CLDN10: A promising OSP-like Protein as a Drug Target or Biomarker

Target Name: CLDN10

NCBI ID: G9071

CLDN10

CLDN10: A promising OSP-like Protein as a Drug Target or Biomarker

Introduction

Clone Degenerate-like 10 (CLDN10) is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer. CLDN10 is a member of the tight junction protein (TJP) family, which is responsible for maintaining tissue barrier integrity. The aberrant expression of CLDN10 has been implicated in various diseases, including cancer, and its potential therapeutic applications have led to its increased interest as a drug target or biomarker.

Disease-Related Role of CLDN10

CLDN10 has been shown to be involved in various physiological processes in the body, including cell signaling, angiogenesis, and inflammation. Several studies have suggested that CLDN10 plays a critical role in the development and progression of various diseases, including cancer.

In cancer, CLDN10 has been shown to be involved in the regulation of cell signaling pathways, such as the PI3K/Akt signaling pathway. This pathway is known to be involved in various cellular processes, including cell growth, survival, and angiogenesis. Studies have shown that CLDN10 can inhibit the activity of the PI3K/Akt signaling pathway, leading to the inhibition of cell proliferation and survival.

In addition to its role in cell signaling pathways, CLDN10 has also been implicated in the regulation of angiogenesis, a process that is critical for the formation of new blood vessels in the body. Studies have shown that CLDN10 can promote the migration of cancer cells, which is critical for their growth and metastasis.

Potential Therapeutic Applications

The therapeutic potential applications of CLDN10 are vast, and its role in cancer alone is estimated to be worth targeting. CLDN10 has been shown to be a potential drug target by various methods, including cell-based assays and animal models of cancer.

One of the most promising strategies for targeting CLDN10 is the use of small molecules that can inhibit its activity. Several studies have shown that various small molecules can inhibit the activity of CLDN10, including inhibitors of the PI3K/Akt signaling pathway, angiogenesis, and cell signaling.

Another approach to targeting CLDN10 is the use of monoclonal antibodies (monos), which are laboratory-produced antibodies that have the same antigen specificity as a natural antibody. Studies have shown that monos can be used to specifically target CLDN10 and inhibit its activity, including the regulation of cell signaling pathways and angiogenesis.

Biomarker Potential

CLDN10 has also been suggested as a potential biomarker for various diseases, including cancer. The detection and quantification of CLDN10 levels in various biological samples, such as tissue samples, blood samples, and urine samples, can be used as a diagnostic or monitoring tool for various diseases.

Studies have shown that CLDN10 levels are often elevated in various diseases, including cancer. The increase in CLDN10 levels can be due to various factors, including the progression of cancer, the development of new blood vessels, and the regulation of cell signaling pathways.

Conclusion

In conclusion, CLDN10 is a protein that has been shown to be involved in various physiological processes in the body, including cell signaling, angiogenesis, and inflammation. Its potential as a drug target or biomarker for various diseases, including cancer, makes it an attractive target for future research. The use of small molecules and monos, as well as the detection and quantification of CLDN10 levels in various biological samples, can lead to the discovery of new therapeutic applications for CLDN10.

Protein Name: Claudin 10

Functions: Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. Involved in the regulation of paracellular epithelia permeability to ions in multiple organs. It acts as a paracellular ion channel probably forming permselective pores; isoform 1 appears to create pores preferentially permeable to cations and isoform 2 for anions. In sweat glands and in the thick ascending limb (TAL) of Henle's loop in kidney, it controls paracellular sodium permeability which is essential for proper sweat production and renal function (PubMed:19383724, PubMed:28771254, PubMed:28686597)

The "CLDN10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLDN10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets